The science
DSIP Research: What the Studies Measured, Across Sleep, Stroke, and Aging
A study-by-study, fully cited walk through the delta sleep-inducing peptide literature — including the parts that did not replicate.
Before the details
The DSIP research record is wide but shallow. Wide, because the peptide has been tested in sleep, seizures, stress hormones, stroke recovery, and even aging. Shallow, because most of the strong findings are in animals or in tiny, decades-old human studies, and because no one has ever found the receptor (docking site) DSIP works through [3].
This page goes study by study. The clearest human result is a six-person insomnia trial from 1981 [2]. The most eye-catching animal results are a stroke-recovery study in rats [9] and a mouse longevity study [5]. And the most important paper of all may be a 2006 review that simply admitted how little is settled [3]. Technical terms are explained in plain words as they come up. None of this is a dosing guide; doses are reported only to describe what was given to which animal in which experiment.
DSIP for sleep: the founding finding and the human data
DSIP's entire identity rests on one 1977 experiment. Schoenenberger and Monnier isolated the nonapeptide from sleeping-rabbit cerebral blood and showed that infusing it into the brain (intracerebroventricularly, meaning directly into the brain's fluid spaces) produced a significant, specific enhancement of delta and spindle EEG activity — the electrical fingerprint of deep sleep [1].
The best human sleep result came in 1981. Six middle-aged people with chronic insomnia received a single intravenous dose of synthetic DSIP at 25 nmol/kg. They slept longer, woke up fewer times, got slightly more REM, and reported no daytime sedation — but the benefit emerged only in the second hour after the injection, with slight arousal in the first hour [2]. It is a genuinely encouraging result, and it is also six people, once, never replicated in a modern controlled trial. That gap between a promising pilot and confirmed efficacy defines DSIP for sleep.
Why the sleep story stayed unresolved
The most honest paper in the literature is a 2006 review in the Journal of Neurochemistry titled 'a still unresolved riddle.' Its conclusions are blunt: the link between DSIP and sleep was never fully characterized; the sleep-promotion hypothesis is 'extremely poorly documented and still weak'; no DSIP gene, protein, or receptor has been isolated; the peptide's brain distribution sits in regions not clearly tied to sleep; and, tellingly, synthetic analogs (not native DSIP) produced the clearest sleep effects [3].
A 2024 study tried to engineer around DSIP's weaknesses. Researchers built a DSIP fusion peptide designed to cross the blood-brain barrier (DSIP-CBBBP) and tested it in mice with chemically induced insomnia. The fusion peptide cut average daily wakefulness by roughly 31% (from about 720 minutes to about 500), restored melatonin, serotonin, and dopamine, produced calming and antidepressant-like behavioral effects, increased hippocampal neuron density — and outperformed unmodified DSIP [6]. The lesson echoes the 2006 review: re-engineered versions of DSIP may matter more than the natural peptide.
Beyond sleep: stress hormones, seizures, and oxygen stress
DSIP's effects spill well past sleep. In men, intravenous DSIP at 25 nmol/kg reduced plasma ACTH-like immunoreactivity (a stress-hormone signal) for at least three hours, while cortisol was unchanged and followed its normal daily decline [4] — though, as a caution, this ACTH effect was not reproduced in other human work. In dissociated pituitary cells, DSIP inhibited both basal and stress-driven ACTH release, and the stress hormones CRF and vasopressin in turn suppressed DSIP secretion, suggesting a two-way relationship with the stress axis [13].
In a rat epilepsy model, DSIP at 0.1-1 mg/kg (most effective at 1 mg/kg) reduced seizure incidence and duration and increased delta-wave EEG power — a dose-dependent anticonvulsant effect [7]. And under experimental low-oxygen stress, DSIP at 120 micrograms/kg protected rat brain mitochondria (the cells' power plants), improved their energy coupling, and curbed lipid peroxidation (oxidative damage to cell membranes) [8]. Separate hypoxia work found DSIP partially restrained stress-driven changes in a brain enzyme and in serotonin, with analogs again acting more strongly than the native peptide [11].
Stroke recovery and ischemia protection
Some of the most concrete recent DSIP work is in stroke models. In adult male rats given a focal stroke, intranasal DSIP at 120 micrograms/kg (eight doses around the stroke) significantly improved motor recovery by day 7. Strikingly, the actual infarct (the dead tissue zone) was not meaningfully smaller — 20.9% versus 24.1% in controls, a non-significant difference — which the authors read as a neuroprotective, function-preserving effect rather than one that shrinks the injury [9].
The interest extends to a DSIP-like molecule. A KND peptide in the DSIP family reduced brain infarction in mice and myocardial (heart-muscle) infarction in rats when given during reperfusion — the moment blood flow is restored after a blockage, which itself causes damage [10]. These are animal findings, and the gap to human stroke care remains large, but they are among the cleaner, more recent results in the field.
The longevity result that needs replication
The most surprising DSIP finding has nothing to do with sleep. In female SHR mice, monthly courses of a DSIP-containing preparation called Deltaran (about 100 micrograms/kg, five consecutive days each month) increased maximum lifespan by 24.1%, extended the lifespan of the last 10% of survivors by 17.1%, cut spontaneous tumor incidence 2.6-fold, and reduced chromosome damage in bone marrow by 22.6% [5].
Those are large numbers, and they deserve a large asterisk. Much of DSIP's lifespan and anti-tumor data comes from a small set of related research groups and has not been independently replicated. As a 'geroprotector' (an agent studied for slowing aging), DSIP is an intriguing lead, not an established one — exactly the pattern that recurs across this entire literature. For the practical research-dosing context behind these studies, see the DSIP dosage page; for the reported human-experience side, see DSIP effects.